# A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

> **NCT01061788** · PHASE1 · COMPLETED · sponsor: **Jeffrey Clarke** · enrollment: 43 (actual)

## Conditions studied

- Advanced Solid Tumors, Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AMG 479, Everolimus, Panitumumab

## Key facts

- **NCT ID:** NCT01061788
- **Lead sponsor:** Jeffrey Clarke
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061788, "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01061788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*